Injectable Cisplatin-Loaded Biodegradable Poly(anhydride-ester) for Treating Head and Neck Cancer: Preclinical
Christine Warwar Damouny1, Narmeen Matta1, Muhammad Abdel Haq2,3
1Intragel Therapeutics LTD., Wadi El Haj 13, PO Box 1252, Nazareth Industrial Area, Nazareth 17111, Israel.
None:
The first-line treatment for unresectable HPV-negative squamous cell carcinoma of head and neck (SCCHN) patients involves weekly or triweekly systemic cisplatin chemotherapy concurrently with radiotherapy. Cisplatin induces severe systemic toxicity that prevents a portion of patients from receiving the standard of care while redirecting them to less effective alternatives. This means worsening prognosis and overall survival (OS). A single-dose long-acting cisplatin limits toxicity. This is an injectable, biodegradable polyanhydride derived from sebacic acid (SA) and ricinoleic acid (RA) investigated as a targeted small-volume, high-payload carrier to improve safety and enhance efficacy.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Site-Targeted Drug Delivery Systems: Polymeric Carriers
